DNp63a is a member of the p53 family of transcription factors that is essential for epithelial maintenance and epidermal morphogenesis (Yang et al. 1998; Mills et al. 1999) . DNp63a is predominantly expressed in epithelial stem cells and undifferentiated basal keratinocytes, where it acts as a critical proliferative factor (Senoo et al. 2007) . DNp63a functions as a potent oncogene in squamous cell carcinomas (SCCs) of diverse origins, where it drives proliferation and blocks apoptosis (Parsa et al. 1999; Rocco et al. 2006) . In fact, DNp63a expression is both a diagnostic marker for specific cancer subtypes and an indicator of poor prognosis (Graziano and De Laurenzi 2011) . Despite its undisputed relevance in epithelial biology and cancer, the mechanism of action of DNp63a remains poorly characterized.
DNp63a contains a DNA-binding domain that is highly conserved with the other p53 family members and binds to DNA response elements nearly identical to those bound by p53, as determined by both in vitro selection of preferred DNA sequences and in vivo genome-wide chromatin-binding studies (Ortt and Sinha 2006; Perez et al. 2007; Kouwenhoven et al. 2010) . However, DNp63a lacks the canonical N-terminal transcriptional activation domain found in p53, TAp63, and TAp73 due to alternative promoter usage within the TP63 locus. Accordingly, DNp63a was found to function as a transcriptional repressor of several genes within the p53 network (Westfall et al. 2003; DeYoung et al. 2006; Rocco et al. 2006; Mundt et al. 2010) . One of the prevailing hypotheses in the literature is that DNp63a represses p53 target genes by simply acting as a dominant negative to prevent p53 occupancy at the shared DNA response elements (Yang et al. 1998 ). According to this view, overexpression of DNp63a in SCCs would broadly shut down the p53 transcriptional program by inactivating this important tumor suppressor at the level of chromatin binding. However, this model is challenged by epidemiological studies showing that most SCCs exhibit a ''gain of function'' in the form of overexpression of DNp63a concurrently with ''loss-of-function'' mutations in p53, indicating that the two oncogenic events are nonredundant during SCC progression (Neilsen et al. 2011 ). This could be explained by the existence of p53-independent oncogenic functions of DNp63a in SCC cells and/or a failure of endogenous DNp63a to act as a true dominant negative of p53 in this cellular context. Deciphering the precise mechanism of action of DNp63a will greatly facilitate the design of therapeutic strategies targeting this oncogene in SCCs.
Here we report the results of our research on the regulatory interactions between endogenous DNp63a and p53 in rare SCC cells expressing wild-type versions of both regulators. Using an isogenic cell system, we found that SCC cells are addicted to DNp63a regardless of p53 status, thus confirming the overall autonomous action of these transcription factors. Intriguingly, our mechanistic studies revealed that although DNp63a and p53 share a large number of DNA response elements in the genome, they regulate largely nonoverlapping subsets of genes. Surprisingly, activated p53 effectively binds to DNp63a-repressed loci but fails to transactivate them. Conversely, DNp63a binds to p53 target genes but fails to repress them. Identification of DNp63a-interacting proteins by mass spectrometry revealed an association with subunits of the SRCAP complex previously implicated in H2A.Z deposition. ChIP analysis revealed that DNp63a mediates recruitment of SRCAP subunits to chromatin as well as H2A.Z deposition. Furthermore, knockdown of SRCAP subunits or H2A.Z leads to specific derepression of DNp63a targets. Finally, we identified SAMD9L as a key anti-proliferative gene repressed by DNp63a, SRCAP subunits, and H2A.Z that is required for the cell proliferation arrest observed upon DNp63a depletion. Thus, our results identify a novel molecular mechanism mediating DNp63a oncogenicity in a p53-autonomous fashion.
Results

DNp63a drives proliferation of SCC cells independently of p53 status
SCCs frequently accrue both loss-of-function mutations of the tumor suppressor p53 and overexpression of the oncogene DNp63a, suggesting that these two oncogenic events are not functionally redundant (Nekulova et al. 2011) . In order to investigate the possible functional interplay between DNp63a and p53, we screened a panel of SCC cell lines in search of those expressing wild-type versions of both genes. Several lines of evidence indicate that H226 cells (lung SCC) express both DNp63a and functional p53. First, Western blot analysis of protein extracts from H226 cells run alongside extracts from insect cells expressing various myc-tagged human p63 isoforms confirmed that H226 cells express only DNp63a and not other p63 variants (Supplemental Fig. 1A ). Second, shRNAs directed against DNp63a-specific mRNA isoforms effectively deplete the Western blot signal from H226 extracts (Fig. 1A) . Third, treatment of H226 cells with Nutlin-3, a specific inhibitor of the MDM2-p53 interaction, leads to effective p53 accumulation and induction of p21 (CDKN1A) and many other well-characterized p53 target genes and results in cell cycle arrest (Fig.   1A ,D,E; Supplemental Figs. 1B, 2). Of note, p53 activation by Nutlin-3 leads to a modest but reproducible decrease in DNp63a expression (Fig. 1A) .
To test for a functional interaction, or lack thereof, between DNp63a and p53 in H226 cells, we established isogenic cell lines stably expressing shRNAs targeting each mRNA (Fig. 1A) . We used a tet-inducible shRNA against DNp63a (referred to herein as shp63), which allowed us to toggle cells between DNp63a-competent and DNp63a-deficient states by simply adding doxycycline to the media. We then tested this inducible shp63 alone or in combination with a stably integrated, constitutively expressed shRNA against p53 (shp53). Upon DNp63a knockdown, primary keratinocytes and various SCC cell lines have been shown to undergo decreased proliferation, increased apoptosis, and/or senescence (Rocco et al. 2006; Truong et al. 2006; Rivetti di Val Cervo et al. 2012) . Upon DNp63a knockdown, H226 cells undergo effective proliferation arrest with little sign of apoptosis, as evidenced by a complete stalling of cell numbers, a decrease in BrdU incorporation, and a drop in S-phase cells without a significant increase in Annexin V staining ( Fig. 1B,C ; Supplemental Fig. 1C-E) . Importantly, this proliferation arrest is completely reversible even after 10 d of DNp63a knockdown, as evidenced by an increase in cell numbers immediately upon doxycycline removal (gray box in Fig. 1B ), indicating that H226 cells do not undergo senescence during DNp63a knockdown. Surprisingly, concomitant knockdown of p53 does not rescue the proliferation arrest caused by DNp63a depletion (Fig. 1B) . However, p53 knockdown alone does increase the proliferation rate of H226 cells, confirming the anti-proliferative effects of p53 in this cell line ( Fig. 1B;  Supplemental Fig. 1C ).
Taken together, these results demonstrate that DNp63a drives proliferation of SCC cells independently of p53 status.
DNp63a and p53 regulate largely nonoverlapping gene expression programs in SCC cells
In order to better understand the autonomous phenotypic effects of DNp63a and p53, we investigated the impact of p53 activation versus DNp63a depletion on global gene expression in H226 cells using microarray analysis. Toward this end, we compared cells treated with Nutlin-3 or doxycycline to induce p53 activation or DNp63a depletion, respectively. Interestingly, the gene set induced by Nutlin-3 treatment showed negligible overlap with the gene set derepressed upon DNp63a knockdown (Fig. 1D ). Nutlin-3 treatment led to significant induction (>1.5-fold, P < 0.05) of 321 genes, including many well-characterized p53 target genes such as p21, BAX, and MDM2 (Supplemental Table 1) . From now on, we refer to this group as class I genes. Using the same cutoff, we found that DNp63a knockdown leads to up-regulation of 215 genes (referred to as class III genes), only seven of which are also up-regulated by Nutlin-3 (class II genes). Importantly, quantitative RT-PCR (qRT-PCR) analysis of several genes within each class validates the microarray results ( Fig. 1E ; Supplemental Fig. 2) . Furthermore, qRT-PCR revealed that class III genes remain insensitive to Nutlin-3-activated p53 even after DNp63a knockdown. Among class I genes, only p21 showed a modest increase in expression in the combination treatment.
These results demonstrate that DNp63a has negligible impact on the p53 transcriptional program in H226 cells, indicating that DNp63a does not function as a broadly acting dominant-negative inhibitor of p53 in this setting. Interestingly, although DNp63a was shown to repress canonical p53 target genes such as p21, 14-3-3s (SFN), GADD45A, PUMA (BBC3), and NOXA (PMAIP1) in some other cell types (Westfall et al. 2003; Rocco et al. 2006) , none of these genes were induced in H226 cells upon DNp63a knockdown ( Fig. 1E; Supplemental Fig. 2) . Thus, we conclude that DNp63a represses a distinct class of genes not activated by p53 in H226 cells. As nearly all of the class II and III genes have not previously been described as being DNp63a target genes, we chose to investigate whether these genes were also transcriptionally repressed by DNp63a in squamous cells of different origins and p53 status. qRT-PCR analysis of HaCaT (immortalized keratinocytes), SCC-13 (head and neck SCC [HNSCC] and tongue), and Cal-27 (HNSCC and oral) cells (all p53 mutant) demonstrates that several class II and III genes, but not class I genes, are similarly upregulated following DNp63a knockdown, indicating that they are bona fide DNp63a target genes (Supplemental Fig. 3) . Furthermore, the differential effects of p53 on class I versus class III genes is still observed when using 5-fluorouracil (5FU), a p53-activating agent that acts by a mechanism different from Nutlin-3 (Supplemental Fig. 4 ). Considering the fact that DNp63a and p53 were found to recognize virtually identical DNA sites both in vitro and in vivo, the lack of coregulation by the two family members in H226 cells prompted us to pose several mechanistic questions. Do p53 and DNp63a bind the same genomic sites in H226 cells? Can the lack of regulatory overlap be explained by yet-unappreciated differences in the chromatin-binding properties of DNp63a and p53? p53 effectively binds to genes repressed by DNp63a but fails to transactivate them In order to investigate the molecular basis of gene-specific regulation by DNp63a and p53, we performed a series of ) were seeded at day 0, and doxycycline was removed from the medium at day 10 to allow re-expression of DNp63a. chromatin immunoprecipitation (ChIP) assays to test their binding to the enhancers of class I, II, and III genes in H226 cells. Detailed maps of each loci tested depicting the location of the DNp63a/p53-binding sites are shown in Supplemental Figure 5 . We used qPCR to analyze ChIPenriched DNA under four experimental conditions: basal (high DNp63a expression and low p53 expression), Nutlin-3 (activated p53), shp63 (low expression of both DNp63a and p53), and Nutlin-3 + shp63 (activated p53 and low DNp63a expression). First, we analyzed p53 binding to chromatin under these conditions. Expectedly, we observed significant p53 binding to all enhancers in class I genes upon Nutlin-3 treatment, albeit with different degrees of occupancy ( Fig. 2A; Supplemental Fig. 6A ). Among these genomic sites, the p21 enhancer displayed the highest p53 occupancy, while the BAX enhancer showed the lowest, yet all of these sites presented significant enrichment over control immunoprecipitations, and all sites demonstrated a significant enrichment of p53 binding following Nutlin-3 treatment as compared with basal conditions. Interestingly, p53 binding was also easily detected at class II and class III genes, with increased occupancy upon Nutlin-3 treatment ( Fig . However, many class II and class III genes showed higher p53 occupancy than most class I genes. For example, EDN2 (class III) shows a level of p53 binding comparable with or higher than that observed at canonical p53 target genes such as FAS and 14-3-3s (class I). Of note, p53 activation with 5FU produces the same overall pattern of p53 binding as that observed with Nutlin-3 (Supplemental Fig. 7 ). Importantly, basal and activated levels of p53 binding to all three gene classes are not increased in cells depleted of DNp63a (cf. red and purple bars in Fig. 2A-C ). This observation argues against the notion that DNp63a competes with p53 for binding to common genomic sites. If anything, p53 binding to some class II and III genes seems to require DNp63a expression (cf. red and purple bars in class II and III Meta-enhancers in Fig. 2A-C) .
Overall, these results demonstrate that p53 effectively binds to genomic sites in all three gene classes but somehow fails to transactivate class III genes.
DNp63a binds to genes activated by p53 and is lost from chromatin upon p53 activation ChIP analysis of DNp63a revealed that, prior to p53 activation by Nutlin-3, DNp63a effectively binds to the genomic sites in all three gene classes ( Fig. 2D-F ; Supplemental Fig. 6D-F) . Interestingly, the levels of DNp63a occupancy across the response elements does not fully correlate with the levels of p53 binding. For example, p53 shows greater than fivefold occupancy at the p53R2 enhancer than the MASPIN enhancer, yet DNp63a binding is similar at these two sites. These differences in relative occupancy between p53 and DNp63a are also observed at class II and III genes. In a similar fashion to p53, the class I genes as a group also show stronger DNp63a occupancy (cf. Y scales in Fig. 2D-F) . However, this trend has many exceptions, with some genes in classes II and III (e.g., TMEM27 and ZHX2) showing greater DNp63a occupancy than most genes in class I. Expectedly, DNp63a ChIP signals decrease considerably at all sites in cells expressing shp63 (cf. black vs. blue bars in Fig.  2D -F). Interestingly, DNp63a occupancy also drops upon Nutlin-3 treatment, most significantly at class I genes (cf. black vs. red bars in Fig. 2D-F ; Supplemental Fig. 6D-F ). This effect could be explained by the decrease in DNp63a expression upon Nutlin-3, as seen by Western blot (Fig.  1A) and/or displacement from chromatin by incoming p53. Of note, the loss of DNp63a binding upon p53 activation is also observed when using 5FU instead of Figure 2 . DNp63a does not prevent p53 access to its genomic sites. ChIP assays were performed with whole-cell extracts from control cells (black bars) following 12 h of 10 mM Nutlin-3 treatment (red bars), 48 h of DNp63a knockdown (blue bars), or the combination of Nutlin-3 treatment and DNp63a knockdown (purple bars). Antibodies specific for p53 (A-C) and DNp63a (D-F) were used. ChIP-enriched DNA was quantified by real-time PCR for the p53/p63 response elements of each indicated gene. See Supplemental Figure 5 for gene maps and amplicon locations. Meta-enhancer values were calculated as the average PCR signal for each treatment group relative to Nutlin-3-treated (p53 IP) or basal (DNp63a IP) values for all response elements tested within a gene class.
Nutlin-3 (Supplemental Fig. 7) . Regardless of mechanism, it is clear that DNp63a does not prevent p53 from accessing its genomic sites.
Taken together, these results show that p53 and DNp63a display a significant overlap in their genomic binding sites yet do not coregulate the hundreds of genes contained in classes I and III. Therefore, their regulatory capacity cannot be solely explained by their chromatinbinding properties.
DNp63a associates with subunits of the SRCAP chromatin regulatory complex involved in histone exchange
The structure of DNp63a contains several protein-protein interaction domains, including a proline-rich domain and a sterile a motif. These domains may enable DNp63a to recruit both positive and negative transcription regulatory factors to its target gene loci. In an unbiased approach to identify DNp63a-interacting proteins, we performed a tandem affinity purification (TAP) of C-terminal Flag/ HA-tagged DNp63a or control GFP proteins followed by SDS-PAGE and mass spectrometry, as previously described (Ramsey et al. 2011) . Interestingly, we found that DNp63a interacts with four proteins previously identified as components of diverse chromatin regulatory complexes: DMAP1 (found in the TIP60 and SRCAP complexes) as well as RUVBL1, RUVBL2, and ACTL6A (found in the TIP60, SRCAP, BAF, and INO80 complexes) ( Fig. 3A ; Supplemental Fig. 8A ; Jin et al. 2005; Huen et al. 2010; Billon and Cô té 2012) . All of these interactions were confirmed by TAP followed by Western blot (Fig. 3B) . Furthermore, fractionation experiments using a 10%-40% glycerol density gradient show that a significant portion of DNp63a copurifies in a large-molecular-weight complex with DMAP1, RUVBL1, RUVBL2, and ACTL6A (Fig. 3C) . Although the SRCAP subunit was not detected by our mass spectrometry protocol, Western blot analysis of the glycerol gradient shows that this subunit copurifies in the same fraction as the rest of the complex (see fraction 11 in Fig. 3C) .
In order to test for the impact of these novel DNp63a interactors on the expression of DNp63a target genes, we established stable knockdowns for subunits of the SRCAP complex as well as subunits of other overlapping protein complexes ( Fig. 3D ; Supplemental Figs. 8B, 9). Interestingly, depletion of the SRCAP subunits SRCAP, ACTR6, ACTL6A, RUVBL1, DMAP1, VPS72, and YEATS4 results in the selective derepression of specific class III genes, including ZHX2, NTN4, SAMD9L, and IGFBP3, with no significant effects on the class I gene p21 ( Fig. 3D ; Supplemental Fig. 8B ). In contrast, knockdown of the non-SRCAP subunits KAT5 (TIP60), EP400 (p400), and INO80 does not produce the same overall pattern of gene-specific derepression. While the precise effect of the six SRCAP subunits tested varies across class III genes, overall, our results implicate subunits of the known SRCAP complex in mediating transcriptional repression by DNp63a.
Depletion of DNp63a leads to loss of H2A.Z and RNA polymerase II (RNAPII) activation Both the SRCAP complex and a smaller subcomplex composed of RUVBL1, RUVBL2, DMAP1, and ACTL6A have been shown to exchange histone H2A with the histone variant H2A.Z (Jin et al. 2005; Choi et al. 2009; Huen et al. 2010; Billon and Cô té 2012) . Interestingly, H2A.Z has been previously identified as a transcriptional repressor in some settings (Gé vry et al. 2007; Marques et al. 2010 ). These observations led us to hypothesize that DNp63a could use this complex as a corepressor, perhaps via H2A.Z deposition. To investigate this possibility, we performed ChIP analysis of the class III gene ZHX2, which was derepressed to varying degrees upon the loss of any of DNp63a, SRCAP, ACTR6, ACTL6A, DMAP1, RUVBL1, RUVBL2, VPS72, and YEATS4 (Figs. 1E, 3D ). ZHX2 is a zinc finger homeobox transcription factor that has recently been shown to induce cell cycle arrest via repression of S-phase cyclins in hepatocellular carcinoma cells (Yue et al. 2012) . ZHX2 is also commonly downregulated in lung SCCs and HNSCCs as well as large cell lung carcinoma and invasive breast carcinoma (Supplemental Fig. 10 ) and thus may be a relevant target of DNp63a-mediated repression during oncogenesis. ChIP assays show that under basal conditions, strong DNp63a binding is detected at the intronic ZHX2 enhancer site but not elsewhere across the gene locus ( Fig. 4A ; Supplemental Fig. 11A ). Expectedly, DNp63a signals drop significantly in cells expressing shp63. ChIP analysis of the actively initiating form of RNAPII [Ser5-phosphorylated (S5P)-RNAPII] shows that DNp63a knockdown increases RNAPII activity at the ZHX2 promoter. Analysis of DMAP1 and RUVBL2 occupancy indicates that both factors are found at the ZHX2 promoter and enhancer sites ( Fig. 4A;  Supplemental Fig. 11A ). Importantly, DNp63a depletion leads to a significant decrease in the binding of these factors exclusively at the enhancer site. Analysis of H2A.Z throughout the ZHX2 locus showed significant occupancy at the promoter region and to a lesser extent at the intragenic enhancer, and DNp63a knockdown leads to a significant drop in H2A.Z signals at both sites ( Fig. 4A ; Supplemental Fig. 11A ). Thus, DNp63a promotes H2A.Z deposition, possibly through a mechanism that involves gene looping from the enhancer to the promoter. Given that H2A.Z has been found to colocalize with CTCF to bridge and loop DNA (Millau and Gaudreau 2011) , it is not necessarily surprising that the DNp63a-specific deposition of H2A.Z may be mediated by the action of these subunits at the distal enhancer site. Of note, DNp63a knockdown also causes decreased occupancy of DMAP1 and RUVBL2 at the enhancers of the class III genes NTN4, SAMD9L, and IGFBP3 as well as reduced H2A.Z signals at the promoters of NTN4 and SAMD9L (Supplemental Fig. 12) . Overall, these results suggest that DNp63a-mediated recruitment of SRCAP subunits and H2A.Z deposition could mediate transcriptional repression at DNp63a target genes. As a first test of this hypothesis, we examined the impact of DMAP1 knockdown. Depletion of DMAP1 led to concomitant loss of H2A.Z and increase in S5P-RNAPII at the ZHX2 promoter ( Fig. 4B; Supplemental Fig. 11B ). Furthermore, DNp63a binding was modestly but reproducibly reduced upon DMAP1 depletion, suggesting a self-enforcing mechanism of recruitment between DNp63a and its corepressor ( Fig. 4B; Supplemental Fig. 11B ).
H2A.Z functions as a specific repressor of DNp63a target genes
Next, we investigated the impact of H2A.Z knockdown on cellular behavior and expression of p53 and DNp63a target genes. H2A.Z knockdown in H226 cells produces a strong decrease in cell viability, as evidenced by a reduction in total cell numbers and BrdU incorporation, and, more prominently, an increase in the number of apoptotic cells ( Fig. 5A-C; Supplemental Fig. 13 ). Strikingly, qRT-PCR analysis revealed that H2A.Z depletion produces a specific increase in the expression of class III genes such as ZHX2, NTN4, SAMD9L, and IGFBP3 (Fig.  5D ). In contrast, the class I genes p21, BAX, and MDM2 were unaffected by H2A.Z knockdown. Among class II genes, FAM49A and GGT6 also showed increased expression, while GJB4 and PLAC8 were unaffected. Thus, H2A.Z knockdown largely mimics the effects of DNp63a knockdown across the three gene classes. To define the generality of these effects, we tested the effects of H2A.Z knockdown in other cell types overexpressing DNp63a and lacking functional p53. In fact, H2A.Z depletion in HaCaT, SCC-13, and Cal-27 cells leads to a specific increase in the expression of the class III genes, most notably ZHX2 and SAMD9L, without significant effects on class I genes (Fig. 5E ). Intriguingly, IGFBP3 was not sensitive to H2A.Z depletion in these cell lines.
Overall, our observations indicate that DNp63a, H2A.Z, and subunits of known H2A.Z exchange complexes function coordinately to repress the transcription of class III genes independently of p53 status. Since DNp63a is required for binding of H2A.Z and recruitment of SRCAP subunits to these loci, our results indicate that DNp63a uses H2A.Z deposition to repress RNAPII activity at these genomic sites.
SAMD9L is a novel anti-proliferative gene repressed by DNp63a and H2A.Z In order to investigate the biological significance of gene repression by the DNp63a/H2A.Z axis, we aimed to define the contribution of class III genes to the proliferation arrest caused by DNp63a depletion. We hypothesized that the arrest phenotype could be driven by up-regulation of one or more anti-proliferative genes normally repressed by DNp63a via H2A.Z. To test this possibility, we established a series of stable knockdowns for validated class III genes in cell lines carrying inducible shp63. We selected genes that have previously been described as antiproliferative (e.g., IGFBP3, NTN4, TP53INP2, and ST14) and/or whose expression is often down-regulated in cancer tissues (e.g., SAMD9L, CAPN13, GBP2, HCP5, and ZHX2). As previously shown in Figure 1 , H226 cell cultures stop dividing when shp63 expression is turned on. Interestingly, among the nine genes tested, only concurrent knockdown of SAMD9L or IGFBP3 leads to an increase in cell numbers (Fig. 6A) . Most strikingly, a time-course experiment revealed that depletion of SAMD9L suffices to rescue the proliferation arrest caused by DNp63a knockdown (Fig. 6B) . A second shRNA targeting SAMD9L reproduces this result, indicating that it is unlikely to be due to off-target effects (Supplemental Fig. 14) . Knockdown of IGFBP3, a previously characterized anti-proliferative target of DNp63a-mediated repression (Barbieri et al. 2005) , using two different shRNAs ( Fig. 6B; Supplemental  Fig. 14) also allowed cell cultures to continue proliferation upon DNp63a depletion. Expectedly, single knockdowns of SAMD9L and IGFBP3 do not affect cell proliferation in DNp63a-proficient cells, as these genes are expressed at very low basal levels ( Fig. 6B; Supplemental Fig. 14, right  panel) .
Taken together, these results show that gene repression mediated by DNp63a and H2A.Z contributes to the hyperproliferative nature of SCC cells and accounts, at least in part, for the oncogenic properties of DNp63a.
Discussion
DNp63a plays critical roles in normal development and cancer. TP63 knockout mice show profound defects in limb, craniofacial, and epithelial development . Exon-specific knockout experiments showed that these developmental effects are not driven by the TA isoforms (Suh et al. 2006; Romano et al. 2012 ). In fact, DNp63a is a proliferative factor required for maintenance of the stem cell population in stratified epithelia (Senoo et al. 2007 ). In humans, loss-of-function germline mutations in the TP63 gene cause a plethora of human ectodermal syndromes (Rinne et al. 2007 ). In the context of cancer, DNp63a is an oncogene that promotes cell survival and proliferation and whose overexpression is widespread among SCCs of multiple origins, including head and neck, lung, and esophagus Yamaguchi et al. 2000) . Despite its undisputed biomedical relevance, the molecular mechanisms of DNp63a action remain obscure. It is generally accepted that DNp63a can function as both a positive and negative regulator of transcription, but it is unclear exactly how these functions contribute to its developmental roles and oncogenic potential. Here we demonstrate that DNp63a is a robust transcriptional repressor of anti-proliferative genes in SCC cells, acting through a previously uncharacterized mechanism involving the recruitment of SRCAP subunits and deposition of the histone variant H2A.Z. Our findings can be summarized as follows: (1) DNp63a is required for proliferation of SCC cells independently of p53 status. (2) DNp63a is a transcriptional repressor of a unique subset of genes that are bound by p53 yet are not transactivated by this tumor suppressor. (3) DNp63a does not prevent p53 binding to its enhancer sites, which contrasts with the view of DNp63a action as a dominant p53 inhibitor. (4) DNp63a associates with and recruits subunits of the SRCAP complex, and knockdown of SRCAP subunits results in up-regulation of DNp63a target genes. (5) The histone variant H2A.Z is deposited in a DNp63a-dependent manner at DNp63a target loci, and H2A.Z knockdown activates these genes. (6) SAMD9L, a gene repressed by DNp63a, SRCAP subunits, and H2A.Z, is required to sustain the proliferation defect observed upon DNp63a loss. Altogether, these results not only advance our understanding of the molecular mechanism of action of DNp63a, but also point to the H2A.Z exchange complexes as important DNp63a cofactors and to SAMD9L as a key antagonist of DNp63a proliferative effects.
The view that DNp63a acts as a dominant-negative inhibitor of p53 was originally proposed based on the observations that DNp63a lacks a canonical transactivation domain and that overexpression of DNp63a inhibits p53 transactivation in ectopic expression reporter assays (Yang et al. 1998; Parsa et al. 1999 ). This notion gathered additional support from the fact that p53 and DNp63a bind to nearly identical DNA sequences both in vitro and in vivo (Ortt and Sinha 2006; Yang et al. 2006; Perez et al. 2007; Kouwenhoven et al. 2010) . In contrast, our research into a possible functional interplay between endogenous p53 and DNp63a in cancer cells normally expressing both proteins forced us to discard the dominant-negative hypothesis, leading us instead to an alternative model whereby DNp63a represses transcription through a chromatin-based mechanism involving recruitment of a chromatin regulatory complex and H2A.Z deposition.
Our proteomics efforts to uncover novel DNp63a cofactors led us to four proteins previously identified as components of diverse chromatin regulatory complexes: DMAP1 (TIP60 and SRCAP complexes) as well as RUVBL1, RUVBL2, and ACTL6A (TIP60, SRCAP, BAF, and INO80 complexes) (Supplemental Fig. 8A ). The sophisticated combinatorial assembly of these proteins into various chromatin regulators known to exert both positive and negative roles in transcription prevents a straightforward interpretation of these interaction data. However, knockdown of subunits that are specific to the SRCAP complex leads to differential up-regulation of DNp63a target genes in our system, which is not observed for non-SRCAP subunits, indicating that SRCAP or a closely related complex functions as a corepressor complex acting at DNp63a target loci. Although the precise effect of each SRCAP subunit varied across DNp63a targets, none of them contributed to repression of the p21 gene, which in our system is not repressed by DNp63a. Collectively, these observations led us to focus on H2A.Z, whose deposition into nucleosomes can be mediated by either a smaller ) were seeded at day 0. Cells were pretreated with doxycycline for 5 d prior to seeding to induce DNp63a knockdown. Isogenic H226 cell lines with stable SAMD9L knockdown or IGFBP3 knockdown were compared with DNp63a knockdown alone (Control). See Supplemental Figure 14 for a second shRNA for each of SAMD9L and IGFBP3. (C) DNp63a recruits subunits of the SRCAP complex and mediates H2A.Z incorporation to repress RNAPII at anti-proliferative genes in a mechanism that is autonomous of p53.
cofactor complex containing the four core subunits interacting physically with DNp63a or a larger complex containing SRCAP itself (Choi et al. 2009; Billon and Cô té 2012) . Indeed, ChIP analysis of the ZHX2 locus shows that DNp63a mediates recruitment of DMAP1 and RUBVL2 and H2A.Z deposition. Unfortunately, our efforts to detect other subunits of the SRCAP complex at DNp63a target loci were unsuccessful, mostly due to the lack of ChIP-grade antibodies (data not shown). More importantly, depletion of H2A.Z leads to specific induction of DNp63a target genes across multiple cell types, suggesting that this histone variant is a downstream effector of DNp63a-mediated repression.
H2A.Z is an evolutionarily conserved variant of the core histone H2A with diverse roles in transcriptional control. Depending on the context, H2A.Z has been described as a positive or negative regulator of transcription. In budding yeast, H2A.Z nucleosomes are observed flanking the transcription start site (TSS), with a nucleosome-free region in between (Raisner et al. 2005) . A similar observation was made in human cells, but in this case, H2A.Z was also found at enhancers and insulators (Barski et al. 2007 ). In yeast, H2A.Z promoter occupancy correlates inversely with transcriptional activity (Guillemette et al. 2005) . In humans, the role of H2A.Z is more enigmatic, as H2A.Z incorporation has been associated with both gene activation and repression (Marques et al. 2010; Billon and Cô té 2012) . In contrast to that observed in yeast, genome-wide studies in human cells show that H2A.Z promoter occupancy correlates positively with gene expression (Barski et al. 2007 ). Intriguingly, biochemical in vitro assays using mammalian factors showed that H2A.Z-containing nucleosomes are refractory to transcription (Thakar et al. 2010) . These seemingly contradictory observations could be reconciled by the precise location of H2A.Z-containing nucleosomes at or near the promoter and the consequent topological effects on transcription factor binding (Marques et al. 2010) . Recent genome-wide approaches have demonstrated that while H2A.Z is deposited both immediately upstream of and downstream from the TSSs of active genes, it is uniformly deposited across the promoter of inactive genes (Valdé s-Mora et al. 2012) . Thus, H2A.Z may regulate transcription positively by reprogramming nucleosome positioning to allow access to a regulatory region or TSS or negatively by preventing access to that regulatory region or TSS (Marques et al. 2010 ). This hypothesis has been supported by recent H2A.Z ChIP-seq (ChIP combined with deep sequencing) studies performed during mitotic silencing, whereby H2A.Z mediates the upstream shifting of the +1 nucleosome to occupy the TSS and thereby reduces the nucleosome-depleted region, thus silencing gene expression. In this manner, H2A.Z serves to transiently repress transcription during mitosis and poise genes for activation upon H2A.Z removal (Kelly et al. 2010) . Future studies will be aimed at deciphering the precise mechanisms by which H2A.Z represses DNp63a target genes.
It is important to note that the mechanism of transcriptional repression described here involving H2A.Z does not exclude other mechanisms used by DNp63a in other contexts. For example, p63 depletion leads to TAp73-dependent apoptosis in various HNSCC cell lines concurrently with up-regulation of PUMA and NOXA (DeYoung et al. 2006; Rocco et al. 2006) . In these cells, DNp63a forms hetero-oligomers with TAp73b and prevents binding of TAp73b to the enhancer site in the PUMA locus. Furthermore, our previous work in other HNSCC cell types demonstrated that DNp63a physically associates with the histone deacetylases HDAC1 and HDAC2, recruits HDAC1, and promotes histone deacetylation at the PUMA locus (Ramsey et al. 2011) . In fact, DNp63a-overexpressing cells are significantly more sensitive to HDAC inhibitors, which elicit a form of cell death that can be blocked by BCL2 overexpression (Ramsey et al. 2011) . Interestingly, these mechanisms are not conserved in the p53-proficient lung SCC cells used in this study. First of all, H226 cells undergo arrest, not apoptosis, in response to DNp63a knockdown. Second, PUMA is not induced upon DNp63a knockdown (Supplemental Fig. 2 ). Third, concomitant knockdown of DNp63a and p73 in H226 cells does not rescue the effects of DNp63a loss in terms of either cell proliferation arrest or target gene expression (data not shown). Fourth, DNp63a depletion has no significant effect on various histone acetylation events analyzed at class I, II, and III genes in H226 cells (data not shown). These context-dependent differences, and particularly the contribution of TAp73 to DNp63a-dependent effects in different SCC cells, may in part reflect the higher TAp73 levels observed in SCCs that express mutant p53 (DeYoung et al. 2006) . Clearly, DNp63a seems to use multiple alternative mechanisms of repression, one of which involves H2A.Z deposition. Importantly, H2A.Z knockdown leads to up-regulation of DNp63a target genes in other cell types beyond H226, including HaCaT (immortalized keratinocytes), SCC-13 (tongue HNSCC), and Cal-27 (oral HNSCC), thus proving the conservation of this mechanism. Future studies will further investigate the basis for these cell and contextdependent mechanisms of repression, which may also be due to differential availability of corepressors.
Depending on the context, diverse sets of genes have been identified as targets of DNp63a-mediated repression, including canonical p53 target genes such as p21, 14-3-3s, PUMA, and NOXA (Westfall et al. 2003; Rocco et al. 2006) . Interestingly, H2A.Z incorporation has been shown to repress the p53 target gene p21 in colorectal cancer cells (Gé vry et al. 2007 ); however, p21 was not repressed by DNp63a, SRCAP subunits, or H2A.Z in the four cell types tested in our study. Instead, our efforts point to a different set of DNp63a-repressed genes that contribute to its oncogenic potential. Our study is unique in that we used an unbiased microarray approach in rare SCC cells of lung origin that expresses functional p53 as well as high levels of DNp63a. Interestingly, analysis performed through The Cancer Genome Atlas (TCGA; https://tcga-data.nci.nih. gov/tcga) indicates that 196 of the 215 genes up-regulated upon DNp63a knockdown in H226 cells have a reduced expression in numerous lung SCC cells as compared with normal tissue (Supplemental Tables 1, 2 ). Studies of SCC cells expressing endogenous DNp63a differ in the degree to which canonical p53 target genes, including p21, MDM2, BAX, NOXA, or PUMA, are repressed by DNp63a (Barbieri et al. 2005; Rocco et al. 2006; Gu et al. 2008; Lu et al. 2011 ). Here our efforts revealed a group of anti-proliferative genes repressed by DNp63a across SCC cell types of diverse origin regardless of p53 status, including IGFBP3 and SAMD9L, whose knockdown rescues the proliferation arrest caused by DNp63a depletion in H226 cells.
IGFBP3 was originally characterized as a p53 target gene whose secretion inhibits mitotic signaling by the insulin-like growth factor IGF-1 (Buckbinder et al. 1995) . However, p53 activation does not lead to IGFBP3 induction in H226 cells and other cell types tested ( Fig. 1 ; data not shown), suggesting that its regulation by p53 is not universal. In contrast, IGFBP3 seems to be a common target of DNp63a-mediated repression, as first characterized by the Pietenpol laboratory (Barbieri et al. 2005) . They showed that DNp63a knockdown leads to IGBFP3 induction in keratinocytes and diverse SCC cell lines, that DNp63a binds to specific sequences in the IGFBP3 locus to mediate repression, and that expression of DNp63a and IGFBP3 is inversely correlated in normal and cancerous tissues (Barbieri et al. 2005) . Our studies confirm and extend these findings. Intriguingly, whereas we found that IGFBP3 is commonly induced upon DNp63a knockdown in H226, HaCaT, SCC-13, and Cal-27 cells, the effects of H2A.Z knockdown are unique to H226 cells, thus reinforcing the notion of cell type-specific mechanisms of corepression by DNp63a.
To the best of our knowledge, we are the first to report SAMD9L as a target of DNp63a-mediated repression. Little is known about the biological roles of SAMD9L. Interestingly, SAMD9L and its paralog gene, SAMD9, exist in a short fragment of the human chromosome 7q21 region that is commonly deleted in patients with myeloid leukemia and myelodysplastic syndrome (Asou et al. 2009 ). SAMD9L is expressed at significantly lower levels in breast carcinomas relative to normal breast epithelia from the same patients (Li et al. 2007) . SAMD9L is ubiquitously expressed across normal tissues (Li et al. 2007 ) and commonly down-regulated in various cancers, including lung SCC as well as large and small cell lung carcinomas (Supplemental Fig. 15 ). Thus, SAMD9L may be a novel tumor suppressor whose repression is key to the oncogenic effects of DNp63a. Our future efforts will focus on the mechanisms of action of SAMD9L and its role in cell proliferation control.
In conclusion, the results presented here demonstrate a novel chromatin-based mechanism by which DNp63a promotes cell proliferation through transcriptional repression in SCCs. These findings pave the road for not only more mechanistic studies, but also the design of therapeutic strategies targeting the DNp63a/H2A.Z pathway in SCCs of multiple tissue origins.
Materials and methods
Cell culture
H226 cells were grown in RPMI-1640 medium, and HEK293FT, HaCaT, SCC-13, and Cal-27 cells were grown in DMEM medium, all supplemented with 10% (v/v) fetal bovine serum (Sigma-Aldrich) and antibiotic/anti-mycotic mix (Invitrogen) under controlled 5% CO 2 and 37°C.
shRNA-mediated knockdown
Isogenic cell lines stably transduced with inducible shRNAs targeting p63 (shp63) or H2A.Z (shH2A.Z) were established using the lentiviral-based shRNA delivery vector pTRIPZ (Open Biosystems). shp53 was expressed using the lentiviral vector pLL3.7. All other shRNAs were generated using the pLKO lentiviral vector (Sigma-Aldrich). For all dual knockdown experiments, shp63 was expressed using the inducible lentiviral vector pLKOTet-On (Novartis). All shRNA sequences are listed in Supplemental Table 3 . We produced viral particles in HEK293FT cells and used the viral particles to transduce H226 cells, which were subsequently cultured in the presence of 5 mg/mL puromycin (pTRIPZ, pLKO) or 2 mg/mL G418 (pLL3.7, pLKO-Tet-On). Transduced HaCaT, SCC-13, and Cal-27 cells were selected with 0.4 mg/mL, 0.5 mg/mL, and 0.5 mg/mL puromycin, respectively. Expression of shp63 was induced using 1 mg/mL (pTRIPZ) or 2 mg/mL (pLKO-Tet-On) doxycycline, and shH2A.Z was induced using 2 mg/mL doxycycline.
Cell proliferation and flow cytometry analyses
For cell proliferation assays, H226 cells were either counted directly using a Cellometer Auto T4 (Nexcelom Biosciences) or subjected to sulforhodamine B (SRB) assays as described previously (Vichai and Kirtikara 2006) . Cell cycle analysis was performed on ethanol-fixed cells using propidium iodide, as described previously (Gomes et al. 2006) . For BrdU incorporation analysis, actively growing cells were pulsed with 10 mM BrdU prior to harvest, fixation, anti-BrdU staining, and propidium iodide counterstaining. For apoptosis index assays, cells were trypsinized and washed in PBS and then in Annexin V-binding buffer (10 mM HEPES at pH 7.4, 140 mM NaCl, 2.5 mM CaCl 2 ). Cells were then stained with Annexin V-fluorescein conjugate (Invitrogen) and propidium iodide, following the manufacturer's instructions. Flow cytometry analysis was performed on a CyAn flow cytometer (Beckman Coulter) or a C6 flow cytometer (Accuri).
Protein immunoblot analysis
Ten micrograms of total protein extract was loaded onto 8% (p53, p63, or Nucleolin) or 15% (p21, H2A.Z, or actin) SDS-PAGE gels and transferred to PVDF membranes. Blots were probed with the indicated primary antibodies (Supplemental Table 4 ) and developed with HRP-conjugated secondary antibodies (Santa Cruz Biotechnology) and ECL detection reagents (GE Healthcare). Blots were imaged on the LAS4000 chemiluminescence imager (GE Healthcare).
Microarray gene profiling
H226 cells were grown to 50%-60% confluence and treated with 1-2 mg/mL doxycycline for 48 h to induce shp63 or 10 mM Nutlin-3 (Cayman) for 12 h to activate p53. Total RNA was isolated using TRIzol (Sigma-Aldrich), following the manufacturer's instructions. Samples were labeled and hybridized to Human Gene 1.0 ST arrays (Affymetrix) according to the manufacturer's instructions. Raw data from the *.CEL files were imported into Partek Express (Partek, Inc.) for analysis. Genes were identified as being significantly induced if they displayed a >1.5-fold change and P < 0.05 as compared with control
